Published in Transplantation on January 01, 2016
Clinically relevant interpretation of solid phase assays for HLA antibody. Curr Opin Organ Transplant (2016) 0.76
Impact of preformed donor-specific antibodies against HLA class I on kidney graft outcomes: Comparative analysis of exclusively anti-Cw vs anti-A and/or -B antibodies. World J Transplant (2016) 0.75
Successful kidney transplantation after desensitization in a patient with positive flow crossmatching and donor-specific anti-HLA-DP antibody: A Case report. Medicine (Baltimore) (2016) 0.75
Identification of patients at risk for renal impairment after living donor kidney transplantation. Langenbecks Arch Surg (2016) 0.75
KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation (2017) 0.75
Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med (2008) 6.60
Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med (2016) 5.31
Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med (2014) 4.70
Embryonic ductal plate cells give rise to cholangiocytes, periportal hepatocytes, and adult liver progenitor cells. Gastroenterology (2011) 3.19
Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med (2012) 2.98
Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis (2011) 2.75
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol (2010) 2.51
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol (2013) 2.47
Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood (2009) 2.33
Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol (2009) 2.08
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology (2011) 2.01
Hepatitis E virus genotype 3 diversity, France. Emerg Infect Dis (2009) 1.99
The CD46-Jagged1 interaction is critical for human TH1 immunity. Nat Immunol (2012) 1.97
Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant (2005) 1.84
A classification of ductal plate malformations based on distinct pathogenic mechanisms of biliary dysmorphogenesis. Hepatology (2011) 1.84
Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol (2005) 1.79
Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis (2010) 1.75
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol (2006) 1.73
Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation. J Am Soc Nephrol (2009) 1.72
Hepatitis E virus and neurologic disorders. Emerg Infect Dis (2011) 1.70
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation (2016) 1.68
Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J Exp Med (2005) 1.67
Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor. Nat Immunol (2012) 1.61
Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood (2006) 1.61
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int (2011) 1.53
An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. Transplantation (2015) 1.52
Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology (2005) 1.52
Laparoscopic radical prostatectomy in renal transplant recipients. Urology (2009) 1.52
Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol (2013) 1.50
Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (2005) 1.49
Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant (2010) 1.48
Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal. Clin Transplant (2002) 1.48
Anti-human leukocyte antigen immunization after early allograft nephrectomy. Transplantation (2012) 1.47
Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. Clin J Am Soc Nephrol (2012) 1.46
Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: prevalence, relevance, and impact on organ allocation. Transplantation (2014) 1.45
Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux. Urology (2009) 1.45
Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome. Am J Hum Genet (2004) 1.45
Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology (2010) 1.44
The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation (2004) 1.44
Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation (2010) 1.44
Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant (2007) 1.43
Psoriasiform eruptions during anti TNF-alpha treatment: psoriasis or not? Arch Dermatol (2007) 1.41
Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation (2007) 1.41
Long-term expansion of effector/memory Vdelta2-gammadelta T cells is a specific blood signature of CMV infection. Blood (2008) 1.39
Occult hepatitis C virus infection in hemodialysis patients: examining the evidence. Am J Kidney Dis (2009) 1.39
Hepatitis E virus strains in rabbits and evidence of a closely related strain in humans, France. Emerg Infect Dis (2012) 1.37
Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am J Pathol (2006) 1.36
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36
Villous atrophy induced by mycophenolate mofetil in renal-transplant patients. Transpl Int (2004) 1.31
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation (2010) 1.28
Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells. J Immunol (2004) 1.26
Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl (2010) 1.26
Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol (2010) 1.17
OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation (2013) 1.14
Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis (2004) 1.14
Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France. Emerg Infect Dis (2011) 1.13
Good performance of immunoglobulin M assays in diagnosing genotype 3 hepatitis E virus infections. Clin Vaccine Immunol (2009) 1.13
A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation (2003) 1.13
Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation (2011) 1.13
Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. Am J Transplant (2004) 1.11
Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother (2010) 1.10
Hepatitis E virus quasispecies and the outcome of acute hepatitis E in solid-organ transplant patients. J Virol (2012) 1.09
Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis (2004) 1.09
Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis. Arthritis Rheum (2007) 1.09
Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant (2005) 1.08
Prevalence of cryoglobulinemia and serological markers of autoimmunity in human immunodeficiency virus infected individuals: a cross-sectional study of 97 patients. J Rheumatol (2003) 1.08
Antibody-dependent anti-cytomegalovirus activity of human γδ T cells expressing CD16 (FcγRIIIa). Blood (2011) 1.08
ADAM17-mediated shedding of FcγRIIIA on human NK cells: identification of the cleavage site and relationship with activation. J Immunol (2013) 1.07
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
Oxalate nephropathy associated with chronic pancreatitis. Clin J Am Soc Nephrol (2011) 1.06
Reconstitution of immunodeficient SCID/beige mice with human cells: applications in preclinical studies. Toxicology (2007) 1.05
Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives. Free Radic Biol Med (2008) 1.05
GFR estimation using standardized cystatin C in kidney transplant recipients. Am J Kidney Dis (2012) 1.05
USPIO-enhanced MR imaging of macrophage infiltration in native and transplanted kidneys: initial results in humans. Eur Radiol (2007) 1.03
A clinical scoring system highly predictive of long-term kidney graft survival. Kidney Int (2010) 1.03